FAST NEWS: Zai Lab’s Loss Widens as R&D Costs Surge

The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) on Thursday reported a $161 million net loss in the third quarter, 67% wider than its $96.41 million loss a year earlier. Looking up: Revenue for the quarter rose 33.5% to $57.54 million, benefiting from a 39% jump in revenue for its core oral oncology drug, Zejula, which generated $39.2 million. Take Note: The company’s R&D expenses jumped 81% to $99.5 million during the period, equal to 173% of its total revenue. Selling, general and administrative expenses also rose 13% to…

Read More »

No Happiness in ‘Double 11’ Shopping Fest for Depressed Alibaba

The e-commerce giant may record its first-ever sales decline in this year’s ‘Double 11’ online shopping extravaganza as its shares sink to their 2014 IPO level Key Takeaways: Alibaba’s merchandise sales for this year’s ‘Double 11’ festival, also known as ‘Singles’ Day,’ could drop 1.5% year-on-year, according to a Bloomberg forecast The company’s depressed stock has recently traded as low as $58.01, below the $68 price from its blockbuster New York IPO in 2014 By Fai Pui The shopping fest known as “Singles’ Day” in China has been a goldmine…

Read More »

Rebounding Atour Nears IPO Finish Line With Slashed New York Offering

The upscale hotel operator’s ninth updated prospectus for a U.S. listing lowers its fundraising target to $62 million from previous $350 million Key Takeaways: Atour has slashed the fundraising target for its long-delayed U.S. IPO plan to $62 million from a previous $350 million The upscale hotel operator’s latest prospectus shows its business rebounded sharply in the third quarter after a big slowdown in the first half of the year By Doug Young If any single company can be said to represent all the ups and downs for U.S.-listed Chinese…

Read More »